Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...
The global Alopecia Treatment Market is poised for significant growth, with the market estimated to be valued at USD 12.5 billion in 2025 and forecasted to reach USD 30.5 billion by 2035 ...
Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...